Stockscreener 앱 받기
56.93
0.14%
0.08
시간 외 거래:
56.93
전일 마감가:
$56.85
열려 있는:
$57.21
하루 거래량:
1.74M
Relative Volume:
1.14
시가총액:
$5.37B
수익:
$536.20M
순이익/손실:
$-45.64M
주가수익비율:
-106.45
EPS:
-0.5348
순현금흐름:
$-28.94M
1주 성능:
-4.22%
1개월 성능:
-15.32%
6개월 성능:
+87.02%
1년 성능:
+135.05%
1일 변동 폭
$56.34
$57.53
1주일 범위
$56.23
$61.87
52주 변동 폭
$22.59
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
56.93 | 5.60B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재확인 | Citigroup | Buy |
| 2025-06-11 | 재개 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm - TradingView
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain? - Simply Wall Street
RTRX5376243 Bond Profile: Coupon and Redemption - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $89.00 - GuruFocus
Travere Therapeutics Is Maintained at Buy by Guggenheim - moomoo.com
Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada
Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace
Travere receives patent allowance for FILSPARI use in FSGS - Investing.com
Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026 - Yahoo Finance
Why Everyone Is Watching Travere Therapeutics (TVTX) Today - Simply Wall Street
Travere Therapeutics appoints new CEO Bradley Campbell - The Globe and Mail
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - Yahoo Finance
TVTX Reiterated by Wedbush -- Price Target Maintained at $76.00 - GuruFocus
Travere Therapeutics Names Bradley Campbell CEO - Contract Pharma
Wedbush reiterates Outperform rating on Travere Therapeutics, $76 price target - TradingView
HC Wainwright & Co. reiterates Buy rating on Travere Therapeutics, $67 price target - TradingView
TVTX Looks 64.1% Overvalued on GF Value™ - GuruFocus
Travere Therapeutics Announces Planned Chief Executive Officer Transition - BioSpace
Travere Therapeutics stock falls amid CEO transition news By Investing.com - Investing.com Nigeria
Travere Therapeutics Names Bradley Campbell CEO Effective December 1, 2026 - Minichart
Travere Therapeutics stock falls amid CEO transition news - Investing.com
Travere Therapeutics CEO Eric Dube to step down in December By Investing.com - Investing.com Australia
Travere Therapeutics President and CEO Eric Dube Plans to Step Down - marketscreener.com
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026 - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum - ChartMill
Travere Therapeutics CFO Cline Christopher R. Executes Options and Sells Shares on September 15, 2026 - Kalkine Media
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing - marketscreener.com
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Canada
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com Australia
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere therapeutics CEO Eric Dube sells $25.4m in shares By Investing.com - Investing.com Canada
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) EVP Sells $10,955,439.31 in Stock - MarketBeat
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Travere Therapeutics Inc 주식 (TVTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ROTE WILLIAM E. | Chief Research Officer |
Sep 15 '26 |
Option Exercise |
21.57 |
78,650 |
1,696,864 |
194,395 |
| ROTE WILLIAM E. | Chief Research Officer |
Sep 16 '26 |
Sale |
63.33 |
112,850 |
7,146,644 |
98,197 |
| ROTE WILLIAM E. | Chief Research Officer |
Sep 15 '26 |
Sale |
62.25 |
96,198 |
5,988,753 |
98,197 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 16 '26 |
Option Exercise |
14.19 |
172,717 |
2,451,533 |
289,783 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 15 '26 |
Option Exercise |
18.31 |
77,190 |
1,413,039 |
219,256 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
22.40 |
8,282 |
185,517 |
125,348 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 16 '26 |
Sale |
63.43 |
172,717 |
10,956,088 |
117,066 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 15 '26 |
Sale |
62.26 |
102,190 |
6,362,825 |
117,066 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Sale |
65.07 |
8,282 |
538,917 |
117,066 |
| Inrig Jula | EVP, Head of R&D & CMO |
Sep 15 '26 |
Option Exercise |
8.93 |
32,395 |
289,287 |
145,165 |
0.05%
0.82%
자본화:
|
볼륨(24시간):